These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 21175545)

  • 21. The effect of ultrapure dialysate on improving renal anemia.
    Go I; Takemoto Y; Tsuchida K; Sugimura K; Nakatani T
    Osaka City Med J; 2007 Jun; 53(1):17-23. PubMed ID: 17867630
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Erythropoietin requirements: a comparative multicenter study between peritoneal dialysis and hemodialysis.
    Coronel F; Herrero JA; Montenegro J; Fernandez C; Gandara A; Conesa J; Rivera MT; Torrente J; Portolés J; Gomez-Martino JR
    J Nephrol; 2003; 16(5):697-702. PubMed ID: 14733416
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
    Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
    Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
    Li H; Wang SX
    Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of oral prostaglandin analogue on painful diabetic neuropathy: a double-blind, randomized, controlled trial.
    Shin S; Kim KJ; Chang HJ; Lee BW; Yang WI; Cha BS; Choi D
    Diabetes Obes Metab; 2013 Feb; 15(2):185-8. PubMed ID: 22974254
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
    Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U;
    Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preventive effect of an oral prostacyclin analog, beraprost sodium, on digital necrosis in systemic sclerosis. French Microcirculation Society Multicenter Group for the Study of Vascular Acrosyndromes.
    Vayssairat M
    J Rheumatol; 1999 Oct; 26(10):2173-8. PubMed ID: 10529135
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Erythropoietin and transfusions in patients with anemia of chronic renal failure origin : an update view].
    Duclos J; Olea C; Aguirre H; Alvarez MC; Salgado MC
    Rev Med Chil; 1995 Apr; 123(4):451-5. PubMed ID: 8525189
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of beraprost sodium (BPS) in a new rat partial unilateral ureteral obstruction model.
    Takenaka M; Machida N; Ida N; Satoh N; Kurumatani H; Yamane Y
    Prostaglandins Leukot Essent Fatty Acids; 2009; 80(5-6):263-7. PubMed ID: 19464862
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness of beraprost sodium in maintaining vascular access patency in patients on hemodialysis.
    Kim M; Kim JU; Kim SM; Kim H
    Int Urol Nephrol; 2017 Jul; 49(7):1287-1295. PubMed ID: 28409403
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral Beraprost sodium, a prostaglandin I(2) analogue, for intermittent claudication: a double-blind, randomized, multicenter controlled trial. Beraprost et Claudication Intermittente (BERCI) Research Group.
    Lièvre M; Morand S; Besse B; Fiessinger JN; Boissel JP
    Circulation; 2000 Jul; 102(4):426-31. PubMed ID: 10908215
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of long-term administration of a prostacyclin analogue (beraprost sodium) on myocardial fibrosis in Dahl rats.
    Kaneshige T; Saida Y; Tanaka R; Soda A; Fukushima A; Ida N; Takenaka M; Yamane Y
    J Vet Med Sci; 2007 Dec; 69(12):1271-6. PubMed ID: 18176024
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Double-blind, Placebo-controlled, Multicenter, Prospective, Randomized Study of Beraprost Sodium Treatment for Cats with Chronic Kidney Disease.
    Takenaka M; Iio A; Sato R; Sakamoto T; Kurumatani H;
    J Vet Intern Med; 2018 Jan; 32(1):236-248. PubMed ID: 29131397
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics and vasodilating effect study of beraprost sodium in healthy volunteers.
    Li P; Zhang R; Yuan G; Chen K; Liu H; Wang Y; Shaikh AS; Wang B; Li R; Guo R
    Pak J Pharm Sci; 2020 Jul; 33(4):1659-1664. PubMed ID: 33583799
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibitory Effects of Beraprost Sodium in Murine Hepatic Sinusoidal Obstruction Syndrome.
    Nakura M; Miyashita T; Yamamoto Y; Takada S; Kanou S; Tajima H; Takamura H; Ohta T
    Anticancer Res; 2020 Sep; 40(9):5171-5180. PubMed ID: 32878805
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of Pharmacokinetic Profiles of Beraprost Sustained Release in Japanese, Chinese, and Korean Healthy Adult Males.
    Nakajo I; Inoue H; Inaba M; Oikawa K; Katashima M; Sawamoto T; Kurumatani H; Shiramoto M
    Clin Drug Investig; 2021 Jun; 41(6):549-555. PubMed ID: 33913081
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Beraprost sodium versus clopidogrel for preventing vascular thromboembolic events of arteriovenous fistula in uraemic patients: a retrospective study with a mean 3-year follow-up.
    Wan Z; Zhu Y; Yang R; Zhang Y; Yang C; Cao L; Yan W; Wang Q; Li N; Zhao M; Gui K; Xiong M
    J Int Med Res; 2019 Jan; 47(1):252-264. PubMed ID: 30270798
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of Beraprost sodium on subjective symptoms in diabetic patients with peripheral arterial disease.
    Yoon HS; Choi WJ; Sung IH; Lee HS; Chung HJ; Lee JW
    Clin Orthop Surg; 2013 Jun; 5(2):145-51. PubMed ID: 23730480
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Pharmacokinetics of Beraprost Sodium Following Single Oral Administration to Subjects With Impaired Kidney Function.
    Shimamura M; Miyakawa J; Doi M; Okada K; Kurumatani H; Mori Y; Oshida K; Nakajo I; Oikawa K; Ushigome F; Miyashita A; Isono M; Miyamoto Y
    J Clin Pharmacol; 2017 Apr; 57(4):524-535. PubMed ID: 27681484
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of beraprost sodium, an oral prostaglandin i2 analog, on hemostatic factors and inflammation in chronic peritoneal dialysis patients.
    Kim KM; Kim HW; Lee JH; Chang JW; Park JS; Kim SB
    Perit Dial Int; 2009; 29(2):178-81. PubMed ID: 19293355
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.